Biological parameters for the choice of antiangiogenic therapy and efficacy monitoring

International Journal of Biological Markers

Volumn 14, Issue 4, 1999, Pages 214-217

  Ziche, M ^a,b   Sorriso, C ^c   Parenti, A ^c   Brogelli, L ^c   Tricarico, C ^c   Villari, D ^a   Pazzagli, M ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c Università di Firenze ^*

Author keywords

Angiogenesis; Angiogenic factor; Antiangiogenic therapy; End point; Quantitative RT PCR

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANTI VEGF; BATIMASTAT; CAI; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 12; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; N1 (1 CARBAMOYL 2,2 DIMETHYLPROPYL) 2 [3 (4 CHLOROPHENYL)PROPYL] N4 HYDROXYBUTANEDIAMIDE; PACLITAXEL; PRINOMASTAT; THALIDOMIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; BIOPSY; CANCER; CARCINOGENESIS; CONFERENCE PAPER; DRUG CHOICE; DRUG EFFICACY; HUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033374689     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400404     Document Type: Conference Paper

References (18)

1. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-88.
2. Ziche M, Morbidelli L, Donnini S. Angiogenesis. Exp Nephrol 1996; 4: 1-14.
3. Folkman J. Angiogenesis in cancer, vascular rheumatoid and other disease. Nat Med 1995; 1: 27-31.
4. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Canc Inst 1992; 84: 1875-87.
5. Gallo O, Masini E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998; 90: 587-95.
6. Gasparini G, Weidner N, Maluta S, et al. Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous-cell carcinoma. Int J Cancer 1993; 55: 739-44.
7. Albo D, Granik MS, Jhala N, et al. The relationship of angiogenesis to biological activity in human squamous cell carcinomas of the head and neck. Ann Plast Surg 1994; 32: 588-92.
8. Klijanienko J, el-Naggar AK, de Braud F, et al. Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. Cancer 1995; 75: 1649-56.
9. NCI web site: http://207.121.187.155/NCI_CANCER_ TRIALS/zones/PressInfo/Angio/
10. Anderson IC, Shipp MA, Docherty AJP, Teicher BA. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 1996; 56: 715-8.
11. Giavazzi R. Personal communication.
12. Thomas H, Adams M. A phase I clinical trial of the matrix metalloproteinase inhibitor marimastat administered concurrently with carboplatin to patients with relapsed ovarian cancer (abstract). Eur J Cancer 1997; 33: S246
13. Ferrara N. Personal communication.
14. Ziche M, Morbildelli L, Alessandri G, Gullino PM. Angiogenesis can be stimulated or repressed in vivo by a change in the GM3:GD3 ganglioside ratio. Lab Invest 1992; 67: 711-5.
15. Gasparini G. Anti angiogenic drugs as a novel anticancer therapeutic strategy. Which are the most promising agents? What are the clinical developments and indications? Crit Rev Oncol Hematol 1997; 26: 147-62.
16. O'Really MS, Bohem T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 227-85.
17. Gordon MS, Talpaz M, Margolin K, et al. Phase I trial of recombinant humanized monoclonal antivascular endothelial growth factor (anti VEGF MAB) in patients with metastatic cancer (abstract No. 809). Proc ASCO 1998; 17: 210.
18. Strawn LM, Shawver LK. Tyrosine kinases in diseases: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Exp Opin Invest Drugs 1998; 7: 553-73.